How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | Kisspeptin-10 | HCG |
|---|---|---|
| ✓ | — | |
| — | ✓ |
Pathway Map
This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.
What These Compounds Share
Key Differences
Compound Detail
Kisspeptin-10
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Decapeptide · 10 amino acids · Fragment of endogenous kisspeptin
Also known as: KP-10
Tap a target above for a plain-language explanation.
Measured directly in a human IV-bolus PK study (small groups of 4-5 participants each for men, follicular-phase women, and preovulatory women -- no significant difference between groups).
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (1) →
Plasma half-life 3.8±0.3 min (men), 4.1±0.4 min (follicular women), 4.1±0.4 min (preovulatory women) -- no significant difference between groups (P=0.91). Confirmed direct LH/FSH stimulation via KISS1R, with a sexually-dimorphic response depending on cycle phase.
Supports: human_half_life, mechanism_summary
HCG
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Heterodimeric glycoprotein hormone · Endogenous hormone
Tap a target above for a plain-language explanation.
Reported in a randomized three-way crossover study of pituitary-suppressed women (IM vs. SC dosing) -- Tmax ~20h across all arms, elimination half-life ~32-33h regardless of route/dose. This population (pituitary-down-regulated women) is not the same as the healthy-men study also on file for this compound; the two should not be conflated.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (2) →
Peak concentration significantly delayed and half-life prolonged after SC vs IM (both P=0.01); testosterone/LH/FSH responses were equivalent between routes.
Supports: human_half_life
Tmax ~20h and elimination half-life ~32-33h across all three arms, regardless of route/dose. Concludes SC is bioequivalent to IM. This population (pituitary-suppressed women) is distinct from the healthy-men study above -- do not treat the two as interchangeable populations.
Supports: human_half_life
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist